ERNEXA THERAPEUTICS INC (ERNA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.07-0.48%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ERNEXA THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-4.76
Annual ending 2026-12-31
Revenue	—	75.35M
EPS	—	-18.02
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-1.86

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Complete public offering of 19 million shares	The company plans to raise money by selling 19 million shares.	Intact	Public offering fails to complete by 2026-Q2	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q1. The company entered a placement agency agreement to raise capital via a public offering of 19 million shares. Financials show continued net losses and negative cash from operations, indicating ongoing capital needs. The priority is newly stated and capital raising is in progress. Delivery assessment Oct 24, 2026
Resolve Nasdaq minimum bid price issue	It aims to fix Nasdaq listing problems.	Intact	Bid price falls below $1.00 per share next quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q1. The company received a Nasdaq notice for failing to maintain the minimum bid price of $1.00 per share. No revenue data is available, but net losses and operating losses have continued. The priority is newly stated and the regulatory risk remains unresolved. Delivery assessment Oct 24, 2026
Reduce operating losses and cash burn	A primary condition in ERNEXA THERAPEUTICS INC's published investment case. The stated target is Operating loss and cash burn improve from -$5.59M and -$2.26M in 2026-Q1.	Broken	Losses and cash burn worsen or stay at 2026-Q1 levels	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 7 of last 7 quarters. Operating income worsened from negative $2.7M in 2024-Q4 to negative $5.59M in 2026-Q1, then improved to negative $4.1M in 2026-Q2. Cash from operations remained negative, ranging from $3.55M to $4.15M negative. The company continues to experience operating losses and cash burn, indicating limited progress in controlling costs. Delivery assessment Oct 24, 2026
Advance ERNA-101 toward IND filing	Ernexa is advancing its cancer drug ERNA-101 toward a Q3 filing.	Intact	IND filing delayed beyond Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 0
2026-07-25	Unavailable	Unavailable	1 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 0
2026-07-29	Unavailable	Unavailable	1 / 1
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 0
2026-08-01	Unavailable	Unavailable	1 / 0
2026-08-02	Unavailable	Unavailable	1 / 1
2026-08-03	Unavailable	Unavailable	1 / 1
2026-08-04	Unavailable	Unavailable	1 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	1 / 1
2026-08-07	Unavailable	Unavailable	1 / 0
2026-08-08	Unavailable	Unavailable	1 / 1
2026-08-09	Unavailable	Unavailable	1 / 1
2026-08-10	Unavailable	Unavailable	1 / 1
2026-08-11	Unavailable	Unavailable	1 / 1
2026-08-12	Unavailable	Unavailable	1 / 1
2026-08-13	Unavailable	Unavailable	1 / 1
2026-08-14	Unavailable	Unavailable	1 / 0
2026-08-15	Unavailable	Unavailable	1 / 0
2026-08-16	Unavailable	Unavailable	1 / 0
2026-08-17	Unavailable	Unavailable	1 / 0
2026-08-18	Unavailable	Unavailable	1 / 0
2026-08-19	Unavailable	Unavailable	1 / 0
2026-08-20	Unavailable	Unavailable	1 / 0
2026-08-21	Unavailable	Unavailable	1 / 0
2026-08-22	Unavailable	Unavailable	1 / 0
2026-08-23	Unavailable	Unavailable	1 / 0
2026-08-24	Unavailable	Unavailable	1 / 0
2026-08-25	Unavailable	Unavailable	1 / 0
2026-08-26	Unavailable	Unavailable	1 / 0
2026-08-27	Unavailable	Unavailable	1 / 0
2026-08-28	Unavailable	Unavailable	1 / 0
2026-08-29	Unavailable	Unavailable	1 / 0
2026-08-30	Unavailable	Unavailable	1 / 0
2026-08-31	Unavailable	Unavailable	1 / 0
2026-09-01	Unavailable	Unavailable	1 / 0
2026-09-02	Unavailable	Unavailable	1 / 0
2026-09-03	Unavailable	Unavailable	1 / 0
2026-09-04	Unavailable	Unavailable	1 / 0
2026-09-05	Unavailable	Unavailable	1 / 0
2026-09-06	Unavailable	Unavailable	1 / 0
2026-09-07	Unavailable	Unavailable	1 / 0
2026-09-08	Unavailable	Unavailable	1 / 0
2026-09-09	Unavailable	Unavailable	1 / 0
2026-09-10	Unavailable	Unavailable	1 / 0
2026-09-11	Unavailable	Unavailable	1 / 0
2026-09-12	Unavailable	Unavailable	1 / 0
2026-09-13	Unavailable	Unavailable	1 / 0
2026-09-14	Unavailable	Unavailable	1 / 0
2026-09-15	Unavailable	Unavailable	1 / 0
2026-09-16	Unavailable	Unavailable	1 / 0
2026-09-17	Unavailable	Unavailable	1 / 0
2026-09-18	Unavailable	Unavailable	1 / 0
2026-09-19	Unavailable	Unavailable	1 / 0
2026-09-20	Unavailable	Unavailable	1 / 0
2026-09-21	Unavailable	Unavailable	1 / 0
2026-09-22	Unavailable	Unavailable	1 / 0
2026-09-23	Unavailable	Unavailable	1 / 0
2026-09-24	Unavailable	Unavailable	1 / 0
2026-09-25	Unavailable	Unavailable	1 / 0
2026-09-26	Unavailable	Unavailable	1 / 0
2026-09-27	Unavailable	Unavailable	1 / 0
2026-09-28	Unavailable	Unavailable	1 / 0
2026-09-29	Unavailable	Unavailable	1 / 0
2026-09-30	Unavailable	Unavailable	1 / 0
2026-10-01	Unavailable	Unavailable	1 / 0
2026-10-02	Unavailable	Unavailable	1 / 0
2026-10-03	Unavailable	Unavailable	1 / 0
2026-10-04	Unavailable	Unavailable	1 / 0
2026-10-05	Unavailable	Unavailable	1 / 0
2026-10-06	Unavailable	Unavailable	1 / 0
2026-10-07	Unavailable	Unavailable	1 / 0
2026-10-08	Unavailable	Unavailable	1 / 0
2026-10-09	Unavailable	Unavailable	1 / 0
2026-10-10	Unavailable	Unavailable	1 / 0
2026-10-11	Unavailable	Unavailable	1 / 0
2026-10-12	Unavailable	Unavailable	1 / 0
2026-10-13	Unavailable	Unavailable	1 / 0
2026-10-14	Unavailable	Unavailable	1 / 0
2026-10-15	Unavailable	Unavailable	1 / 0
2026-10-16	Unavailable	Unavailable	1 / 0
2026-10-17	Unavailable	Unavailable	1 / 0
2026-10-18	Unavailable	Unavailable	1 / 0
2026-10-19	Unavailable	Unavailable	1 / 0
2026-10-20	Unavailable	Unavailable	1 / 0
2026-10-21	Unavailable	Unavailable	1 / 0
2026-10-22	Unavailable	Unavailable	1 / 0
2026-10-23	Unavailable	Unavailable	1 / 0
2026-10-24	Unavailable	Unavailable	1 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	0	0
2026-06-01	1	0	0
2026-07-01	1	0	0
2026-08-01	1	0	0
2026-09-01	1	0	0
2026-10-01	1	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Complete public offering of 19 million sharesDirect metric needs a verified mapping
Resolve Nasdaq minimum bid price issueDirect metric needs a verified mapping
Reduce operating losses and cash burnPublished status: Broken
Advance ERNA-101 toward IND filingDirect metric needs a verified mapping

Next proof point

Nov 6, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

4.1%Typical daily move · historical

Downside history

-95.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ERNEXA THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making business rather than an established durable compounder. The multi-year view is in a watch state, with low confidence and recent results well below its industry cohort.

What's priced into ERNEXA THERAPEUTICS INC

The valuation model shows a durable premium versus peers, but confidence in that measure is low. The evidence does not explain what expectations support the premium, so how much optimism is already priced in is unclear.

What the fundamentals likely do

Near term, continued operating losses and negative cash from operations point to ongoing funding needs, despite a recent improvement in operating loss. The company is raising capital and addressing a Nasdaq minimum-bid-price notice, while the risk of another earnings miss is elevated. The stronger Healthcare sector backdrop is a support, but it does not resolve ERNA’s company-specific issues.

What ERNEXA THERAPEUTICS INC hinges on

Over the next few quarters, the thesis hinges on whether ERNA can reduce losses and cash burn while addressing listing compliance and its capital needs. A weakening jobs report could weigh on cyclical shares, while strong results from sector bellwethers could sustain Healthcare momentum; misses or weaker guidance from those companies could remove that support.